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Tara Seshadri, Armand KeatingOver the past decade autologous hematopoietic cell transplantation has fallen out of favor as consolidation
therapy for acute myeloid leukemia (AML) in first remission (CR1). This, in part, can be attributed to the
results of a number of prospective trials, many of which compared outcomes of myeloablative HLA-matched
sibling allotransplants with autotransplants using bone marrow-derived autografts. More recent studies, in-
cluding one from the Center for International Blood and Marrow Transplant Research, explore how periph-
eral blood autotransplants, influence outcomes. In this brief review, a rationale for a reexamination of the use
of autotransplants for de novo AML in CR1 is explored.
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Autologous hematopoietic cell transplantation
(AHCT) has improved survival in a number of hemato-
logic diseases including multiple myeloma [1,2],
Hodgkin’s disease [3], aggressive NHL [4], and mantle
cell lymphoma [5]. One area in which the role of
autotransplants remains uncertain is acute myeloid
leukemia (AML).
Despite complete remission rates of 60% to 80%
with anthracycline/cytarabine-based induction ther-
apy in untreated de novo AML, most patients will
relapse. AML is broadly stratified into 3 prognostic
groups based on cytogenetics: only 10% to 15% of pa-
tients have good prognosis AML, characterized by the
t(15:17) translocation or core-binding factor abnor-
malities, whereas 50% to 60% of patients have normal
cytogenetics with an intermediate prognosis, and the
remaining 30% to 40% have an adverse cytogenetic
risk profile characterized by complex cytogenetic rear-
rangements or deletion of chromosomes 5 or 7 [6,7].
Given the heterogeneity of outcomes among AML
patients after conventional chemotherapy, establishing
the optimum role of autotransplants has been challeng-
ing. Nonetheless, several trials have attempted to
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6/j.bbmt.2008.11.016One of the first and largest randomized controlled
trials (RCT) published by the EORTC-GIMEMA
groups in 1995 assigned 623 patients under the age
of 60 years, who were in complete remission after
standard induction and 1 course of intermediate dose cy-
tarabine consolidation (CC) to allogeneic transplant
(based on donor), AHCT, or a second course of consol-
idation [8]. Postremission therapy was received in 85%
of patients assigned to allogeneic transplant, 82%
assigned to CC, and 74% assigned AHCT, and the anal-
ysis performed was on the intention-to-treat (ITT)
principle. Although patients receiving an allogeneic
transplant had a lower relapse rate compared with the
other 2 treatment arms, this advantage was offset by
higher treatment-related mortality (TRM), such that at
4 years no difference in overall survival (OS) was noted.
Of note, a higher disease-free survival (DFS) was evident
in patients assigned to AHCT compared with CC (48%
versus 30%), but again, no difference in OS was seen.
Four subsequent RCT during the era of bone
marrow-derived progenitor cells gave various results
on the impact of AHCT. The French GOELEMs group
[9] randomized patients under the age of 50 years to al-
lotransplant after induction on the basis of donor avail-
ability. Patients with no donor received high-dose
cytarabine-based consolidation (HiDAC) followed by
randomization to AHCT versus a second HiDAC cycle.
Approximately 80% to 85% of patients received the as-
signed postremission therapy (73 of 88 for allo, 75 of 86
for auto, and 71 of 88 for HiDAC). This study found no
difference in DFS or OS between patients receiving an
allogeneic transplant (44% and 53%) and those with
no HLA compatible donor (38% and 53%). In addition,
no difference in DFS was evident in patients assigned to
HiDAC or AHCT.17
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domized patients with no HLA donor under the
age of 60 years in complete remission after 3 courses
of chemotherapy to AHCT or no further treatment.
No advantage in DFS was evident in the AHCT
group. Of note, although 344 patients were theoreti-
cally eligible for randomization, only 130 were actu-
ally randomized. Moreover, only 55% of patients
assigned to AHCT received this therapy and the
data were analyzed by ITT.
The ECOG/SWOG/CALGB intergroup study
[11] randomized patients after 2 courses of idarabucin
and standard dose cytarabine to allogeneic transplant,
AHCT, or a single course of HiDAC. In an ITT anal-
ysis, no difference in DFS was noted between the 3
groups, and OS was marginally better in those receiving
chemotherapy alone. Of note, only 54% of patients as-
signed to AHCT actually received this therapy, in con-
trast to the 91% who received HiDAC and the 81% of
patients receiving allotransplant.
Finally, the MRC-AML 10 trial [12] randomized
381 patients under the age of 56 years after 4 courses
of chemotherapy to no further treatment or AHCT.
Sixty-six percent of patients assigned to AHCT
received the treatment. A superior DFS was noted
at 7 years in the AHCT group: 53% versus 40%
(P5 .04); however, significantly more deaths in remis-
sion occurred in the AHCT arm. Although OS was
higher in the AHCT at 7 years (57% versus 45%),
this did not reach statistical significance.
All of these trials analyzed the outcome of the
assigned postremission therapy on an ITT basis. This
can clearly pose problems in interpretation when a sig-
nificant proportion of patients do not actually undergo
the intended treatment. Reasons for not undergoing
the intended therapy range from patient refusal, toxic-
ity, relapse of leukemia, and protocol violation. In addi-
tion, all these early trials included patients with
favorable cytogenetics—a subgroup that generally
does well with chemotherapy alone [13,14]. Finally,
when these studies were performed, virtually all auto-
transplants were supported with bone marrow-derived
progenitor cells, which have a higher TRM compared
to AHCTs largely because of the longer duration of
hematopoietic recovery.
Three studies in later years have therefore ad-
dressed the question of the utility of AHCT in the
PBSC era. Tsimberidou et al. [15] randomized patients
in complete remission following standard induction
and 1 consolidation course containing HiDAC to
AHCT, allogeneic transplant (if\50 years) or a second
course of HiDAC. Patients with favorable cytogenetics
were excluded from randomization. Of the 120 patients
included in the study, only 15 received alloBMT, 19 re-
ceived AHCT, and 15 received HiDAC. Comparing
AHCT to HiDAC, the 3-year OS and failure free sur-
vival was 58%/42% for AHCT and 46%/33% for theHiDAC group; however, statistical significance was
not reached for either.
In contrast, a large European intergroup trial [16]
evaluated HiDAC induction and escalation of postre-
mission therapy in a 2-stage RCT. Patients under the
age of 60 years were randomized to 1 of 2 induction
courses: double HiDAC induction versus standard
cytarabine-HiDAC induction. Patients in remission
received a third cycle of chemotherapy followed by
a second randomization to AHCT or maintenance
chemotherapy. Fifty-one percent assigned to mainte-
nance received the assigned therapy, although only
24% received the assigned AHCT. Three-year remis-
sion duration was 50% versus 44%, 3-year relapse-free
survival was 48% versus 43% for maintenance and
AHCT, respectively, and there was no significant dif-
ference between the 2 postremission therapies when
stratified according to cytogenetic risk profile.
The EORTC/GIMEMA AML 10 trial [17] per-
formed a donor-versus-no-donor comparison in de
novo AML patientsunder 46 years of age. All patients re-
ceived 2 coursesof chemotherapy before randomization.
In an ITT analysis, the 4-year DFS was superior in the
donor group at 52% versus 42% in the no-donor group;
however, OS was similar. The benefit of allogeneic
transplant was most pronounced in patients with
a poor cytogenetic risk profile with improvement in
4 year DFS and OS seen, and was even greater when pa-
tients over the age of 36 years were excluded. Survival
advantages were not seen in good or intermediate cyto-
genetic risk profiles. Supporting this study were findings
in a recently published meta-analysis of 3 HOVON-
SAKK studies [18], AML 4, AML 29, and AML 42,
which analyzed HLA donor versus no-donor outcome
in 925 patients. A donor was available in 326 and compli-
ance with allogeneic transplantation was 82%. Results
were stratified according to cytogenetic risk profile
and age. DFS and relapse risk were significantly better
in patients with intermediate- and poor-risk cytogenet-
ics and an advantage in OS was seen in patients under
40 years of age.
The CIBMTR has also attempted to address, spe-
cifically, the issue of the impact of peripheral blood
versus marrow autografts using Registry data [19].
An analysis of 1133 patients with AML in first remis-
sion was recently undertaken of patients who under-
went HLA-identical myeloablative bone marrow
(BM) or peripheral blood (PB) allotransplantation or
PB autotransplantation. There were too few cases of
BM autotransplants for analysis. Median ages were
36, 40, and 44 years, respectively. The proportion of
high-risk cytogenetics was 6%, 9%, and 7%, respec-
tively. Cytogenetics were available on 74% to 88%
of patients. Five-year outcomes by univariate analysis
revealed the following for BM allotransplants, PB allo-
transplants, and PB autotransplants: TRM: 19%, 20%,
and 8% (P\ .001), respectively; and survival: 64%,
Biol Blood Marrow Transplant 15:17-20, 2009 19Is There a Role for Autotransplants in AML in First Remission?59%, and 54% (P 5 .19), respectively. These data
suggest that PB autotransplants may be an acceptable
alternative to HLA-matched sibling donor transplan-
tation for patients with AML in first remission but
do not address the issue of its role versus consolida-
tion chemotherapy. Interestingly, cytogenetic risk
category was not a prognostic variable for TRM or
survival.
What can one deduce from this plethora of informa-
tion? It appears that patients under the age of 40 years
with intermediate- or poor-risk cytogenetics are best
managed with an allogeneic transplant, as this offers
the best chance of cure and an acceptable toxicity pro-
file. The small proportion of patients with favorable cy-
togenetics appear to have a good outcome with
chemotherapy alone [13,16]. However, optimum post-
remission therapy for the vast majority of patients—
those older than 40 years with intermediate- or poor-
risk cytogenetics—remains undefined despite the
many RCT performed. Moreover, the division of pa-
tients with intermediate cytogenetics into prognostic
groups based on their molecular signature [20] further
complicates analyses. Supportive care for AHCT has
improved over the years, and CIBMTR data (1995-
2004) derived from 315 reporting centers and 40 coun-
tries indicate that TRM for PB autotransplants is 8%
(likely less in 2009). Furthermore, with new agents
such as the CXCR4 receptor antagonist, AMD 3100
[21] to enhance hematopoietic cell mobilization, fewer
patients will be declined AHCT on the basis of insuffi-
cient progenitor cell collection.
Given these considerations it is timely to consider
the reinvestigation of autotransplants for AML, espe-
cially in conjunction with innovative posttransplant
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